Diagnostic power of one-step and two-step RT-qPCR methods to SARS‑CoV‑2 detection.
COVID-19
Curve
Real-Time PCR
Roc
SARS-COV-2
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
31 May 2022
31 May 2022
Historique:
received:
14
01
2022
accepted:
20
05
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
Coronavirus-2019 (COVID-2019) is a novel coronavirus known as Acute Respiratory Syndrome (SARS-CoV-2). The premier standard test for SARS-CoV-2 diagnosis is a one-step RT-qPCR method, which requires specific probes and reagents. Therefore, detection on a large scale is expensive and cannot be very accurate. A cost-effective technique based on SYBR green was evaluated in the current study. The specific primers for S and N genes were designed, then performed the cross-reactivity test with other coronavirus and respiratory viruses positive samples. Moreover, the analytical sensitivity test was carried out with 8 dilutions (1:10). Lastly, the SARS-CoV-2 clinical samples (n = 210) were tested by these two methods, and receiver operating characteristic (ROC) analysis was performed to investigate the incremental diagnostic value of each gene in the study methods. The two-step method detected up to 6th dilutions of the SARS-CoV-2 samples and did not show any amplification of the positive samples of other respiratory viruses. ROC analysis revealed a diagnostic ability of the two-step method for SARS-CoV-2 with an area under the ROC curve of ≥ 0.7 (P ˂ 0.05) and relatively high sensitivity and specificity. The combination of N and S genes increased the sensitivity up to 88%, specificity up to 86%, and area under the ROC curve up to 0.85 (95% confidence interval (95% CI) 0.72 to 0.93, P = 0.0461). Our findings indicated that the two-step method has comparable sensitivity and specificity to the one-step method. Therefore, this method can be considered a potential diagnostic method for diagnosing and monitoring COVID-19 patients. It suggests that when the one-step RT-qPCR method is not available, the two-step RT-qPCR can be used to identify SARS-CoV-2.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus-2019 (COVID-2019) is a novel coronavirus known as Acute Respiratory Syndrome (SARS-CoV-2). The premier standard test for SARS-CoV-2 diagnosis is a one-step RT-qPCR method, which requires specific probes and reagents. Therefore, detection on a large scale is expensive and cannot be very accurate.
METHODS
METHODS
A cost-effective technique based on SYBR green was evaluated in the current study. The specific primers for S and N genes were designed, then performed the cross-reactivity test with other coronavirus and respiratory viruses positive samples. Moreover, the analytical sensitivity test was carried out with 8 dilutions (1:10). Lastly, the SARS-CoV-2 clinical samples (n = 210) were tested by these two methods, and receiver operating characteristic (ROC) analysis was performed to investigate the incremental diagnostic value of each gene in the study methods.
RESULTS
RESULTS
The two-step method detected up to 6th dilutions of the SARS-CoV-2 samples and did not show any amplification of the positive samples of other respiratory viruses. ROC analysis revealed a diagnostic ability of the two-step method for SARS-CoV-2 with an area under the ROC curve of ≥ 0.7 (P ˂ 0.05) and relatively high sensitivity and specificity. The combination of N and S genes increased the sensitivity up to 88%, specificity up to 86%, and area under the ROC curve up to 0.85 (95% confidence interval (95% CI) 0.72 to 0.93, P = 0.0461).
CONCLUSION
CONCLUSIONS
Our findings indicated that the two-step method has comparable sensitivity and specificity to the one-step method. Therefore, this method can be considered a potential diagnostic method for diagnosing and monitoring COVID-19 patients. It suggests that when the one-step RT-qPCR method is not available, the two-step RT-qPCR can be used to identify SARS-CoV-2.
Identifiants
pubmed: 35641907
doi: 10.1186/s12879-022-07478-0
pii: 10.1186/s12879-022-07478-0
pmc: PMC9152310
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
505Informations de copyright
© 2022. The Author(s).
Références
Virus Res. 2020 Dec;290:198173
pubmed: 32979475
Adv Biomed Res. 2014 Feb 28;3:85
pubmed: 24761393
Osong Public Health Res Perspect. 2020 Feb;11(1):8-14
pubmed: 32149037
Front Immunol. 2020 May 12;11:1022
pubmed: 32574260
Front Cell Infect Microbiol. 2020 Jun 16;10:331
pubmed: 32626666
RNA Biol. 2021 Dec;18(12):2218-2225
pubmed: 33966602
Mol Cell Probes. 2017 Jun;33:36-41
pubmed: 28188840
Sci Rep. 2021 Nov 4;11(1):21658
pubmed: 34737323
Braz J Microbiol. 2020 Sep;51(3):1117-1123
pubmed: 32767275
J Biomed Sci. 2020 Jun 4;27(1):72
pubmed: 32498686
Mol Aspects Med. 2006 Apr-Jun;27(2-3):254-98
pubmed: 16481036
J Virol Methods. 2021 Jul;293:114165
pubmed: 33872650
J Med Virol. 2006 Jun;78(6):760-3
pubmed: 16628591
Sci Rep. 2021 Jan 26;11(1):2224
pubmed: 33500453
Clin Microbiol Rev. 2006 Jan;19(1):165-256
pubmed: 16418529
J Virol Methods. 2021 Mar;289:114035
pubmed: 33285190
PLoS Biol. 2020 Oct 7;18(10):e3000867
pubmed: 33027248
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Rev Esp Quimioter. 2020 Dec;33(6):466-484
pubmed: 33070578
Emerg Microbes Infect. 2020 Dec;9(1):1259-1268
pubmed: 32438868
J Clin Microbiol. 2020 Apr 23;58(5):
pubmed: 32132196